Prognostic and predictive value of CD163 expression and the CD163/CD68 expression ratio for response to adjuvant chemotherapy in patients with surgically resected lung squamous cell carcinoma.
Naoki YanagawaShunsuke ShikanaiMayu SugaiYoshihiko KoikeToshinari AsaiTakayuki TanjiRyo SugimotoMitsumasa OsakabeNoriyuki UesugiHajime SaitoMakoto MaemondoTamotsu SugaiPublished in: Thoracic cancer (2023)
We suggest that M2 TAMs may be a useful marker to predict prognosis and differential benefit from adjuvant chemotherapy in patients with surgically resected lung SCCs.